Point-prevalent abstinence at 4 months 4 months after the quit date [clinicaltrials_resource:c932b0831a89a197c551e0af8e901ba9]
To test our hypothesis that among the subset of the 770 enrolled participants who quit smoking and then lapsed while using the nicotine patch, those randomized to continue the patch post-lapse will be more likely to be 7-day point-prevalent abstinent at 4 month follow-up than those randomized to discontinue the patch post-lapse.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Point-prevalent abstinence at 4 months 4 months after the quit date [clinicaltrials_resource:c932b0831a89a197c551e0af8e901ba9]
To test our hypothesis that among the subset of the 770 enrolled participants who quit smoking and then lapsed while using the nicotine patch, those randomized to continue the patch post-lapse will be more likely to be 7-day point-prevalent abstinent at 4 month follow-up than those randomized to discontinue the patch post-lapse.
Bio2RDF identifier
c932b0831a89a197c551e0af8e901ba9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c932b0831a89a197c551e0af8e901ba9
measure [clinicaltrials_vocabulary:measure]
Point-prevalent abstinence at 4 months
time frame [clinicaltrials_vocabulary:time-frame]
4 months after the quit date
description
To test our hypothesis that am ...... continue the patch post-lapse.
identifier
clinicaltrials_resource:c932b0831a89a197c551e0af8e901ba9
title
Point-prevalent abstinence at 4 months 4 months after the quit date
@en
type
label
Point-prevalent abstinence at ...... 2b0831a89a197c551e0af8e901ba9]
@en